Sumitomo Pharma Co., Ltd.
Supplementary Materials for FY2026 Q2 Financial Results
Published IFRS-based supplementary materials for FY2026 Q2. Revenue was 266.5 hundred million yen, up 17.3% year-over-year; core operating profit declined sharply to 42.1 hundred million yen; overseas sales ratio expanded to 83.2%. Earnings forecasts were revised.
Key Figures
- FY2026 Q2 Revenue: 2,665 hundred million yen
- Core operating profit: 421 hundred million yen
- Profit attributable to owners of parent (interim): 382 hundred million yen
AI要約
Performance Overview
The supplementary materials for Sumitomo Pharma Co., Ltd.'s FY2026 Q2 disclose consolidated results on an IFRS basis. While revenue increased significantly year-over-year, both core operating profit and operating profit declined substantially. The rise in overseas ratio (83.2%) is notable, and foreign exchange effects and changes in cost structure have impacted profitability.
Impact and Outlook
Although revenue is expanding, increased costs and higher research and development spending have depressed profits, particularly resulting in a large decline in core operating profit. Earnings forecasts have been revised, and future currency movements and the progress of new drug development will be key factors.
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
